COMMUNIQUÉS West-GlobeNewswire

-
Q BioMed and Mannin Research to Develop GDF15 Biomarker Glaucoma Diagnostic Kit Through Collaboration with McMaster University
19/03/2019 -
Altimmune Announces Positive Results from NasoVAX Extension Study
19/03/2019 -
VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment
19/03/2019 -
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
19/03/2019 -
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68th Annual Scientific Session
19/03/2019 -
Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial
19/03/2019 -
Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity
19/03/2019 -
Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019
19/03/2019 -
Immutep to Present IMP761 Preclinical Results in Global Webcast
19/03/2019 -
Auxly to Report 2018 Financial Results on March 29, 2019
18/03/2019 -
CORRECTION - IntelGenx to Report Fourth Quarter and Full-Year 2018 Financial Results on March 22, 2019 – Conference Call to Follow on March 25, 2019
18/03/2019 -
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
18/03/2019 -
RavenQuest Completes Non-Brokered Private Placement
18/03/2019 -
aTyr Pharma to Announce Fourth Quarter and Full Year 2018 Financial Results on March 25th
18/03/2019 -
Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
18/03/2019 -
Dermira Announces Proposed Public Offering of Common Stock
18/03/2019 -
Syneos Health Reports Fourth Quarter and Full Year 2018 Results
18/03/2019 -
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
18/03/2019 -
resTORbio, Inc. Announces Proposed Public Offering of Common Stock
18/03/2019
Pages